Isfahan University of Medical Sciences

Science Communicator Platform

Share By
Clinicopathological Correlation of Insulin-Like Growth Factor Binding Protein 3 and Their Death Receptor in Patients With Gastric Cancer Publisher

Summary: Study finds lower IGFBP-3 and IGFBP-3R levels in gastric cancer linked to worse prognosis, highlighting their role as key markers. #GastricCancer #CancerResearch

Ansari A1 ; Gheysarzadeh A2 ; Sharifi A3 ; Mofid MR1
Authors

Source: Research in Pharmaceutical Sciences Published:2024


Abstract

Background and purpose: The insulin-like growth factor binding protein 3 (IGFBP-3) and its novel death receptor (IGFBP-3R) have been exhibited to have tumor suppressor effects. Despite their prognostic value in some cancers, they have not been elucidated in gastric cancer. Experimental approach: We collected 68 samples from patients with gastric cancer. IGFBP-3 and IGFBP-3R expression levels were evaluated with quantitative real-time polymerase chain reaction (RT-PCR) and western blotting in patients. The relationship between prognostic factors and IGFBP-3/IGFBP-3R expression was also evaluated. Findings/Results: Our results showed that IGFBP-3 and IGFBP-3R expression was reduced significantly in tumor tissues. We found that there was an association between the reduction of IGFBP-3 with lymph node metastasis and tumor-node-metastasis (TNM) staging. Besides, IGFBP-3R expression was associated with tumor size, lymph node metastasis, differentiation, and TNM classification. Interestingly, we presented that the downregulation of IGFBP-3R was stage-dependent. In survival analysis, our findings showed that low levels of IGFBP-3R mRNA expression exhibited a close correlation with survival rate. Conclusion and implications: The findings of this study showed that the expression levels of IGFBP-3 and IGFBP-3R are valuable prognostic factors. Despite the potential of IGFBP-3, IGFBP-3R plays a significant role as a prognostic factor in gastric cancer. However, these findings need to be developed and confirmed by further studies. © 2024 Wolters Kluwer Medknow Publications. All rights reserved.